secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2026-07-17T20:07:20+00:00
Accession:  0001401914-26-000040
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Daré Bioscience receives Nasdaq delisting notice for equity deficiency; plans to request hearing
--------------------------------------------------------------------------------

- Nasdaq notified Daré on July 13, 2026 that stockholders' equity was below $2.5M as of March 31, 2026.
- Company also failed alternative compliance measures: $35M market value or $500K net income from continuing ops.
- Daré intends to timely request a hearing before a Nasdaq Hearing Panel to stay delisting.
- No assurance that the Panel will grant an extension or that the company will regain compliance.
- Non-compliance is with Nasdaq Listing Rule 5550(b); delisting risk remains.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000140191426000040/0001401914-26-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000140191426000040/dare-20260713.htm
  HTML page:      https://secwatch.observer/filing/0001401914-26-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer